Acura Pharmaceuticals and Ranbaxy have agreed to settle their patent infringement litigation related to painkiller Aversion (oxycodone hydrochloride), once marketed by Pfizer under its registered trademark Oxecta.
The US Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case that concerns a “no-authorised-generic” settlement between Teva and GlaxoSmithKline (GSK).
Allergan, along with Japan-based Senju and Kyorin have sued Indian pharma Aurobindo for infringing claims in the Japanese pharmaceutical companies’ reexamined US patent 6,333,045.
Bayer AG has agreed to buy New Jersey-based Merck’s consumer care business for $14.2 billion, the companies announced today (May 6).
HGF has promoted Mike Nelson to partner. He joined the firm last year to work with the pharmaceutical and chemistry teams after arriving from AstraZeneca.
Patent protection in the pharmaceutical sector in India has raised “serious” concerns, the US government said yesterday, April 30, in its annual Special 301 Report.
Cephalon has filed another lawsuit to protect its chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma treatment Treanda (bendamustine hydrochloride), this time against Canadian pharmaceutical company Uman Pharma.
Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).
AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.
The US Court of Appeals for the Federal Circuit has thrown out a lower court ruling that found Natco Pharma infringed a patent covering Roche’s flu drug Tamiflu (oseltamivir phosphate).